Status of adjuvant endocrine therapy for breast cancer

Breast Cancer Research

Table 4 Outcomes in relation to specific adverse events in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial[82]

Outcome measure	AE	Number of AEs (yes versus no AE)	Hazard ratio	95% CI	P value
DFS	VMS	249 versus 837	0.731	0.618-0.866	<0.001
	MSAE	239 versus 847	0.826	0.694-0.982	0.030
	VVS	89 versus 997	0.769	0.585-1.01	0.058
	Overall	418 versus 668	0.735	0.632-0.855	<0.001
OS	VMS	147 versus 617	0.583	0.424-0.803	0.001
	MSAE	151 versus 613	0.811	0.654-1.005	0.055
	VVS	51 versus 713	0.570	0.391-0.831	0.003
	Overall	268 versus 496	0.680	0.565-0.819	<0.001
DM	VMS	165 versus 490	0.813	0.664-0.996	0.046
	MSAE	138 versus 517	0.749	0.601-0.934	0.010
	VVS	54 versus 601	0.687	0.435-1.085	0.107
	Overall	261 versus 394	0.783	0.651-0.942	0.010

AE, adverse event; CI, confidence interval; DFS, disease-free survival; DM, distant metastases; MSAE, musculoskeletal adverse event; OS, overall survival; VMS, vasomotor symptoms; VVS, vulvovaginal symptoms.

ISSN: 1465-542X